select trial semaglutide Trial: Cuts Major CVD Risk by 20% in Overweight/Obese Adults Without Diabetes Semaglutide and Cardiovascular Outcomes in

However, there are some more serious potential risks associated with GLP-1 RAs, including semaglutide

Death from cardiovascular causes included both death from cardiovascular cause and death from undetermined causes

Which matters for: Joint health Falls risk Long-term function Aging well Researchers are actively working on next-generation therapies designed to target fat mass while preserving lean mass , reflecting growing recognition that body composition, not just weight, matters for long-term health and function: read more In Canada, an estimated 1 in 7 adults (more than 4 million people) are living with osteoarthritis , and that number is expected to rise significantly over the next decade as the population ages and rates of metabolic disease increase

registered adult obesity prevalence rates of 25% and above in 2024